Adverse Event Management

Brain Cancer

Breast Cancer

Disparities in Cancer Care

Drug Safety

Colorectal Cancer

Liver Cancer

Gastric Cancers

Gastrointestinal Cancer

Genetics

Kidney Carcinoma

Bladder Cancer

Prostate Cancer

Genitourinary Cancer

Endometrial Cancer

Cervical Cancer

Ovarian Cancer

Gynecologic Cancers

Head and Neck Cancers

Leukemia

Multiple Myeloma

Lymphoma

Hematology

Immuno-Oncology

Lung Cancer

Myeloproliferative Neoplasms

Nurse Navigation

Pediatric Cancer

Practice Management

Prevention

Radiation Oncology

Sarcomas

Melanoma

Skin Cancer

Supportive Care

Survivorship

A phase 3 trial based out of India suggests that olanzapine may be useful in reducing chemotherapy-induced nausea and vomiting.

Olanzapine Significantly Reduces CINV in Patients Receiving MEC 

Incorporating frailty screenings into preexisting workflows may be an effective way to provide more holistic care to patients with head and neck cancer. 

Reimagining Frailty Screenings in Head and Neck Cancer

Investigators reflect on the Oncology Care Model and its implications.

Screening for Pain and Depression is Not Enough in Cancer Care

The median overall survival with niraparib, abiraterone acetate, and prednisone was 30.4 months vs 28.6 months with abiraterone acetate and prednisone alone.

Niraparib-Based Triplet Therapy Offers OS Advantage in BRCA1/2+ mCRPC

News

Latest News

FDA News

Survivorship 

Contributors

Media

Podcasts

Videos

Conferences

Conference Coverage

Conference Listing

Publications

CME/CE

Continuing Education

Resources

Oncology Drug Crash Course

Webinars

Cancer Summary Slides

MPN Symptom Management

Subscribe

Print Subscription

eNewsletter

Partners

Lindsay Fischer is an editor at ONN. She joined MJH life sciences in 2021 after graduating from Rutgers University with majors in both English and Spanish and a minor in creative writing. When she is not writing, or researching the latest oncology nursing news, Lindsay is an amateur backpacker and rollerblader. Email Lindsay at lfischer@mjhlifesciences.com

Articles

Experts with the University of Miami Sylvester Comprehensive Cancer Center share their insights. 

Tenets of Counseling Cancer Survivors During Remission 

There have been reports of T-cell malignancies among patients who have undergone CD19- or BCMA-directed autologous CAR T-cell immunotherapies.

FDA Is Investigating Potential Secondary Cancer Risks Associated CAR T-Cell Therapy

Christina M. Wilson, PhD, CRNP, WHNP-BC, shares how providers can help their patients feel empowered during their treatment.

Why a Trauma-Informed Approach Is Ideal in Gynecologic Cancer Care

Finding ways to prevent and manage stress may be key to optimizing clinical outcomes in oncology.

Stress May Inhibit Immunotherapy’s Efficacy in Treating Cancer

CancerNetwork.com

CureToday.com

OncLive.com

TargetedOnc.com

Advertise

Privacy

Terms & Conditions

Do Not Sell My Information

Oncology Nursing News

Facebook

Twitter

Specialty

Advanced Practice Providers

Clinical

Gynecologic Cancer

Immunotherapy

Quality Improvement

1rem

Authors

Robin B. Brenner, RN, CRN, OCN, clinical research nurse, David M. Rubinstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, discusses adverse events associated with Onivyde (irinotecan liposome injection; MM-398) for pancreatic cancer.

Robin Brenner on Side Effects of Onivyde for Pancreatic Cancer 

Robin B. Brenner, RN, CRN, OCN

Articles

Latest Conference Coverage